Genetic Polymorphism of Cytochrome P450 4F2, Vitamin E Level and Histological Response in Adults and Children with Nonalcoholic Fatty Liver Disease Who Participated in PIVENS and TONIC Clinical Trials

Shaminie Athinarayanan¹, Rongrong Wei¹, Min Zhang², Shaochun Bai³, Maret G. Traber⁴, Katherine Yates⁵, Oscar W. Cummings⁶, Jean Molleston⁷, Wanqing Liu¹,8,9, Naga Chalasani¹⁸,9*

¹Department of Medicinal Chemistry and Molecular Medicine, Purdue University, West Lafayette, Indiana, United States of America, ²Department of Statistics, Purdue University, West Lafayette, Indiana, United States of America, ³Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, ⁴Linus Pauling Institute, Oregon State University, Corvallis, Oregon, United States of America, ⁵Johns Hopkins Bloomberg School of Public Health, Baltimore, Massachusetts, United States of America, ⁶Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, ⁷Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, ⁸Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, ⁹Indiana Fatty Liver Disease Research Group, Indiana University School of Medicine, Indianapolis, Indiana, United States of America

Abstract

Vitamin E improved liver histology in children and adults with NAFLD who participated in TONIC and PIVENS clinical trials, but with significant inter-individual variability in its efficacy. Cytochrome P450 4F2 (CYP4F2) is the major enzyme metabolizing Vit E, with two common genetic variants (V433M, rs2108622 and W12G, rs3093105) found to alter its activity. We investigated the relationship between CYP4F2 genotypes, α-tocopherol levels and histological improvement in these two trials. V433M and W12G variants were genotyped in TONIC (n = 155) and PIVENS (n = 213) DNA samples. The relationships between CYP4F2 genotypes, plasma α-tocopherol levels at baseline and weeks 48 (w48) and 96 (w96) and histological end points (overall improvement in liver histology and resolution of NASH) were investigated. As a result, the V433M genotype was significantly associated with baseline plasma α-tocopherol in the TONIC trial (p = 0.004), but not in PIVENS. Among those receiving Vit E treatment, CYP4F2 V433M genotype was associated with significantly decreased plasma α-tocopherol levels at w48 (p = 0.003 for PIVENS and p = 0.026 for TONIC) but not at w96. The w96 α-tocopherol level was significantly associated with resolution of NASH (p = 0.006) and overall histology improvement (p = 0.021) in the PIVENS, but not in the TONIC trial. There was no significant association between CYP4F2 genotypes and histological end points in either trial. Our study suggested the a moderate role of CYP4F2 polymorphisms in affecting the pharmacokinetics of Vit E as a therapeutic agent. In addition, there may be age-dependent relationship between CYP4F2 genetic variability and Vit E pharmacokinetics in NAFLD.

Introduction

Nonalcoholic fatty liver disease (NAFLD) is one of the common liver diseases in both children and adults, and it can lead to cirrhosis, liver failure and liver cancer [1–3]. Weight loss through lifestyle modification is routinely recommended for individuals with NAFLD to improve their liver disease and underlying metabolic risk factors, but weight loss is often unsuccessful. Recently, the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) has conducted two randomized, placebo-controlled clinical trials to improve liver histology in children and adults with NAFLD and NASH, respectively. The “Pioglitazone versus Vitamin E (Vit E) versus Placebo for the Treatment of Non-diabetic Patients with Nonalcoholic Steatohepatitis” (PIVENS) trial compared vitamin E (α-tocopherol, 800 IU per day) or pioglitazone (30 mg/day) against placebo for 96 weeks in 247 adults with NASH [4]. In this trial, Vit E improved a number of histological endpoints including a reduction in the NAFLD activity score (NAS) by ≥ 2 points as well as the resolution of NASH. The “Treatment of Nonalcoholic Fatty Liver
Table 1. Plasma α-tocopherol levels at baseline and during PIVENS and TONIC clinical trials.

|          | PIVENS |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
|----------|--------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|                      |
|          | Entire cohort | Vit E | Piog | PLB | Vit E vs PLB | Piog vs PLB |
|          | Median | Min-Max | Median | Min-Max | Median | Min-Max | Median | Min-Max | Median | Min-Max | p     | p     |
| Baseline α-toco | 0.58* | 0.23–2.00 | 0.61 | 0.28–1.16 | 0.57 | 0.26–2.00 | 0.56 | 0.23–1.01 | - | - |                      |                      |
| α-toco at week 48 | - | - | 1.33 | 0.50–3.29 | 0.56 | 0.21–1.16 | 0.63 | 0.38–1.14 | <0.0001 | - |                      |                      |
| α-toco at week 96 | - | - | 1.22 | 0.49–1.28 | 0.55 | 0.21–1.17 | 0.59 | 0.27–1.22 | <0.0001 | - |                      |                      |
| Week 48/baseline | - | - | 2.18 | 0.97–5.74 | 0.98 | 0.41–2.26 | 1.07 | 0.74–2.63 | <0.0001 | 0.0026 |                      |                      |
| Week 96/baseline | - | - | 1.89 | 0.53–4.54 | 0.91 | 0.34–2.39 | 1.01 | 0.49–2.99 | <0.0001 | - |                      |                      |
|          | TONIC |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
|          | Entire cohort | Vit E | Met | PLB | Vit E vs PLB | Met vs PLB |
|          | Median | Min-Max | Median | Min-Max | Median | Min-Max | Median | Min-Max | Median | Min-Max | p     | p     |
| Baseline α-toco | 0.49 | 0.23–1.70 | 0.48 | 0.30–1.70 | 0.49 | 0.28–0.95 | 0.48 | 0.23–1.42 | - | - |                      |                      |
| α-toco at week 48 | - | - | 1.08 | 0.43–5.06 | 0.53 | 0.26–1.87 | 0.51 | 0.31–1.30 | <0.0001 | - |                      |                      |
| α-toco at week 96 | - | - | 1.08 | 0.46–3.39 | 0.47 | 0.29–0.75 | 0.51 | 0.20–0.95 | <0.0001 | - |                      |                      |
| Week 48/baseline | - | - | 2.14 | 0.64–5.01 | 1.07 | 0.38–3.27 | 1.05 | 0.33–2.8 | <0.0001 | - |                      |                      |
| Week 96/baseline | - | - | 2.07 | 0.48–4.91 | 0.95 | 0.44–1.83 | 1.06 | 0.17–2.24 | <0.0001 | - |                      |                      |

Data are shown as median and range (min-max) of plasma α-tocopherol adjusted for total cholesterol (mg/g).

*Baseline plasma α-tocopherol in PIVENS was significantly higher than the TONIC cohort \( p=4.8 \times 10^{-5} \).

α-toco = α-tocopherol; Piog = Pioglitazone; Met = Metformin; PLB = placebo.

doi:10.1371/journal.pone.0095366.t001
Disease in Children” (TONIC) compared Vit E (\(\alpha\)-tocopherol, 800 IU per day) or metformin (500 mg twice daily orally) against placebo for 96 weeks in 173 children with histologically confirmed NAFLD [5]. In this trial, Vit E significantly improved NAS and hepatocellular ballooning and resolved NASH in a significantly higher proportion of children.

Although both PIVENS and TONIC trials have shown that Vit E improves liver histology in NAFLD, there were remarkable inter-individual differences in the response to Vit E treatment in individuals with NAFLD. In order to investigate this hypothesis, we examined the relationship between these two CYP4F2 SNPs, \(\alpha\)-tocopherol levels before and during treatment as well as histological endpoints in PIVENS and TONIC clinical trials.

### Materials and Methods

#### Ethical statement

This study represents an ancillary study of the NASH CRN and it was reviewed and approved by the steering committee of the NASH CRN. All participants signed an informed consent prior to their participation in the clinical trials and their informed consent allowed for future testing of genomic DNA for clinical investigations. DNA samples of all subjects were received for genotyping after de-identified. The current study used data previously collected from the clinical trials without further intervention with patients.

#### Participants

Participant characteristics have been described in detail in previous publications [11,12]. Subjects with available genomic DNA sample (n = 368) were included in the present study, which consisted of 213 adults from the PIVENS and 155 children from the TONIC clinical trial. Among these patients, 75 adults in the PIVENS clinical trial and 50 children in the TONIC clinical trial received Vit E for 96 weeks. The remaining participants received either placebo or pioglitazone (in case of PIVENS) or metformin (in case of TONIC).

#### Genotyping

Sequences containing the CYP4F2 W12G and V433M polymorphisms were amplified by PCR. The primer sequences for PCR amplification were 5’-CAGGAAGTCCATCCATCGC-3’ for W12G-F; 5’-GGCCCTTTTCTGAGCTTTACGCTTCT-3’ for W12G-R; 5’-CTCTAGAGGCTTGGAGAATTGA-3’ for V433M-F and 5’-CTCCTGACTGCTCCCTTTCTCTC-3’ for V433M-R. PCR reactions were set up in a 25 ul volume using the HotStar Taq Master Mix Kit (Qiagen, CA, USA) with 10 pmol of each primer and 10 ng DNA. DNA amplification was performed in the GeneAmp PCR System 2700 thermal cycler (Applied Biosystems, CA, USA) with the following program: 10 min at 95°C for 1 cycle, followed by 35 cycles of 95°C for 10 s, 58°C for 20 s and 72°C for 40 s and 1 final extension cycle of 72°C for 7 min. PCR products were then purified using the ExoSAP-IT reagent (Affymetrix, CA, USA) according to the manufacturer’s instructions. The purified PCR products were directly sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, CA, USA) according to the manufacturer’s instructions, and the sequencing results and genotypes were read and summarized using the Mutation Surveyor DNA Variant Analysis Software (Softgenetics, PA, USA).

#### Data analysis

\(\alpha\)-tocopherol levels before and during treatment were normalized to the corresponding measurements of total cholesterol, and the ratios were used for the subsequent analyses. For the remainder of the manuscript, \(\alpha\)-tocopherol adjusted for cholesterol was simply referred to as \(\alpha\)-tocopherol. Data were presented as median and range (min and max) of the ratios, while statistical analyses are based on the log transformed (+log10) data. The histological endpoints of interest were: 1) Overall histological improvement (yes or no), defined as at 96 weeks of treatment, and further underline the inter-individual variability in the response to Vit E in individuals with NAFLD. In order to investigate this hypothesis, we examined the relationship between these two CYP4F2 SNPs, \(\alpha\)-tocopherol levels before and during treatment as well as histological endpoints in PIVENS and TONIC clinical trials.

### Table 2. Association between \(\alpha\)-tocopherol level during treatment and histological endpoints among Vit E treated participants in PIVENS and TONIC.

| Response | Yes | No | p value |
|----------|-----|----|---------|
|          | Median | Min-Max | Median | Min-Max |
| PIVENS   |       |       |         |         |
| NASH Resolution* |       |       |         |         |
| \(\alpha\)-toco at week 48 | 1.33 | 0.57–2.21 | 1.31 | 0.50–3.29 | 0.006 |
| Week 48/baseline | 2.29 | 0.97–5.74 | 2.05 | 1.42–4.9 |
| Week 96/baseline | 1.8 | 0.53–3.13 | 2.03 | 0.85–4.54 | 0.006 |
| Overall Improvement* |       |       |         |         |
| \(\alpha\)-toco at week 48 | 1.28 | 0.57–2.69 | 1.37 | 0.50–3.29 |         |
| Week 48/baseline | 2.22 | 0.97–5.74 | 2.09 | 1.42–3.83 |         |
| Week 96/baseline | 1.88 | 0.84–3.24 | 1.99 | 0.85–4.42 |         |
| TONIC    |       |       |         |         |
| NASH Resolution* |       |       |         |         |
| \(\alpha\)-toco at week 48 | 1.29 | 0.57–5.06 | 0.99 | 0.43–1.85 |         |
| Week 48/baseline | 2.18 | 0.64–5.01 | 2.15 | 1.14–3.48 |         |
| Week 96/baseline | 2.22 | 0.48–3.35 | 1.55 | 1.18–4.91 |         |
| Overall Improvement* |       |       |         |         |
| \(\alpha\)-toco at week 48 | 1.11 | 0.43–1.91 | 1.07 | 0.48–5.06 |         |
| Week 48/baseline | 2.25 | 0.64–4.29 | 2.10 | 1.08–5.01 |         |
| Week 96/baseline | 2.05 | 0.48–3.34 | 2.13 | 1.02–4.91 |         |

*See text for definitions.

doi:10.1371/journal.pone.0095366.t002
whether or not there is improvement in ballooning score by 1 point, while no increase in the fibrosis score; and either a decrease of the NAS score to 3 points OR a decrease in NAS of at least 2 points with at least a 1 point decrease in either the lobular inflammation or steatosis score; 2) Resolution of NASH, defined as the absence of steatohepatitis on the week 96 liver biopsy; 3) Improvement in steatosis, lobular inflammation or hepatocyte ballooning (yes or no), defined as improvement in steatosis, lobular inflammation and hepatocyte ballooning by 1 point at 96 weeks. The analyses were performed separately for individuals participating in PIVENS and TONIC clinical trials.

Comparison of the α-tocopherol levels (log transformed ratios for baseline, at weeks 48 and 96, as well as the ratios between levels at week 48 or 96 and baseline) between PIVENS and TONIC participants (baseline for all genotyped participants, week 48, 96 measurements and the ratios for Vit E treated patients), and between each treatment arm and placebo was performed using ANOVA test. Non-parametric Kruskal-Wallis test was performed for those samples that fail to meet normal distribution assumptions. ANOVA test was also used to test the associations between α-tocopherol levels and histological endpoints. Relationships between CYP4F2 polymorphisms and α-tocopherol levels were tested using a linear regression model assuming an additive effect of the M allele at the V433M locus and a recessive model for the G allele at the W12G locus, given the very low frequency of the GG genotype (GG% = 0.013). Chi-square test or Fisher’s exact test were used to examine the Hardy-Weinberg Equilibrium (HWE) and genetic associations between V433M and histological endpoints. The V433M was tested based on a 2×3 contingency table, while W12G was based on a 2×2 table after combining the GG and WG genotype groups, again due to low frequency of the GG genotype. Statistics were

Figure 1. Association between CYP4F2 V433M polymorphism and α-tocopherol levels at baseline (entire cohort) and during the intervention phase (in Vit E treated participants) in PIVENS and TONIC trials. Data shown in Box (horizontal bar in the box indicates median) and whiskers plot (with 10–90 percentile). Panel A: Relationship between V433M genotype and baseline α-tocopherol level in PIVENS (p = ns). Panel B: Relationship between V433M genotype and baseline α-tocopherol level in TONIC (p = 0.004). Panel C: Relationship between V433M genotype and week 48 α-tocopherol level in PIVENS (p = 0.004). Panel D: Relationship between V433M genotype and week 48 α-tocopherol level in TONIC (p = 0.0002).

doi:10.1371/journal.pone.0095366.g001
Comparison of Vit E levels between active treatment and placebo groups

Among individuals receiving Vit E, the plasma α-tocopherol levels increased by about 2-fold at 48 and 96 weeks relative to their baseline levels. The ratios between the measurements at week 48 or 96 and the baseline level measured before treatment were significantly higher in the patients who received Vit E compared with those who received placebo (p<0.0001 in PIVENS and <0.0001 in TONIC). As expected, there was no difference in the α-tocopherol level among children treated with metformin at weeks 48 and 96, either relative to their baseline or the placebo group (Table 1). Similarly, the α-tocopherol levels did not change significantly at weeks 48 and 96 in adults in the PIVENS trial who received pioglitazone (Table 1). In order to clarify whether the difference was significantly attributed to the differences in cholesterol level, the absolute values of plasma α-tocopherol levels were also compared. A similar result was observed (Table S2).

Relationship between α-tocopherol levels and histological response in the Vit E treatment group

Surprisingly, the α-tocopherol levels at week 96 (but not at week 48) were significantly lower among Vit E treated PIVENS adults who exhibited resolution of NAS (p = 0.006) or overall improvement in histology (p = 0.02) (Table 2). Similar results were observed for absolute values of plasma α-tocopherol levels, suggesting these associations were not affected by the cholesterol levels (Table S3). A similar pattern was not observed among Vit E treated children in the TONIC trial (Table 2). There was no significant association between α-tocopherol levels during treatment and improvement in steatosis, fibrosis, ballooning and inflammation (data not shown). There was also no significant association between the baseline α-tocopherol levels and any of the histological endpoints in either of the clinical trials (data not shown).

Relationship between CYP4F2 polymorphisms and α-tocopherol levels

There was significant correlation between V433M genotype and baseline α-tocopherol level among children in the TONIC trial (all participants, correlation coefficient r = 0.23, p = 0.001), where the M allele was shown an additive effect on Vit E metabolism causing a higher relative α-tocopherol level (Fig. 1A and 1B). However, no such association was noted in the PIVENS trial.

Among participants receiving Vit E, the V433M polymorphism was significantly associated with higher α-tocopherol levels at week 48 in both PIVENS (r = −0.35, p = 0.004) and TONIC (r = −0.34, p = 0.026) trials (Table 3, Fig 1C and 1D). This association in PIVENS was stronger (r = −0.43, p = 0.0002), when using the ratio between the measurements at week 48 and baseline (data not shown). As shown in Table 3, there was no association between CYP4F2 genotypes and α-tocopherol levels at week 96 in either clinical trial.

Comparison of Vit E levels between active treatment and placebo groups

Among individuals receiving Vit E, the plasma α-tocopherol levels increased by about 2-fold at 48 and 96 weeks relative to their baseline levels. The ratios between the measurements at week 48 or 96 and the baseline level measured before treatment were significantly higher in the patients who received Vit E compared with those who received placebo (p<0.0001 in PIVENS and <0.0001 in TONIC). As expected, there was no difference in the α-tocopherol level among children treated with metformin at weeks 48 and 96, either relative to their baseline or the placebo group (Table 1). Similarly, the α-tocopherol levels did not change significantly at weeks 48 and 96 in adults in the PIVENS trial who received pioglitazone (Table 1). In order to clarify whether the difference was significantly attributed to the differences in cholesterol level, the absolute values of plasma α-tocopherol levels were also compared. A similar result was observed (Table S2).

Relationship between α-tocopherol levels and histological response in the Vit E treatment group

Surprisingly, the α-tocopherol levels at week 96 (but not at week 48) were significantly lower among Vit E treated PIVENS adults who exhibited resolution of NAS (p = 0.006) or overall improvement in histology (p = 0.02) (Table 2). Similar results were observed for absolute values of plasma α-tocopherol levels, suggesting these associations were not affected by the cholesterol levels (Table S3). A similar pattern was not observed among Vit E treated children in the TONIC trial (Table 2). There was no significant association between α-tocopherol levels during treatment and improvement in steatosis, fibrosis, ballooning and inflammation (data not shown). There was also no significant association between the baseline α-tocopherol levels and any of the histological endpoints in either of the clinical trials (data not shown).

Relationship between CYP4F2 polymorphisms and α-tocopherol levels

There was significant correlation between V433M genotype and baseline α-tocopherol level among children in the TONIC trial (all participants, correlation coefficient r = 0.23, p = 0.001), where the M allele was shown an additive effect on Vit E metabolism causing a higher relative α-tocopherol level (Fig. 1A and 1B). However, no such association was noted in the PIVENS trial.

Among participants receiving Vit E, the V433M polymorphism was significantly associated with higher α-tocopherol levels at week 48 in both PIVENS (r = −0.35, p = 0.004) and TONIC (r = −0.34, p = 0.026) trials (Table 3, Fig 1C and 1D). This association in PIVENS was stronger (r = −0.43, p = 0.0002), when using the ratio between the measurements at week 48 and baseline (data not shown). As shown in Table 3, there was no association between CYP4F2 genotypes and α-tocopherol levels at week 96 in either clinical trial.

Association between CYP4F2 polymorphisms and histological response

There was no significant association between either SNP and overall histological improvement or resolution in NAS in either clinical trial (Table 4). Similarly, when the analyses were limited to those who received Vit E, no significant association was observed between CYP4F2 polymorphisms and any of the histological endpoints in either clinical trial (Table 4). There were statistically significant associations noted between V433M genotypes and

---

**Table 3.** Association between CYP4F2 polymorphisms and plasma α-tocopherol levels.

|                | V433M | W12G |
|----------------|-------|------|
|                | r     | p    | r     | p    |
| **PIVENS**     |       |      |       |      |
| Baseline α-toco| 0.01  | -    | 0.04  | -    |
| α-toco at week 48| −0.35| 0.003| −0.17 | -    |
| α-toco at week 96| −0.18| -    | −0.14 | -    |
| Week 48/baseline| −0.43| 0.0002| −0.27| 0.019|
| Week 96/baseline| −0.22| -    | −0.20 | -    |
| **TONIC**      |       |      |       |      |
| Baseline α-toco| −0.23| 0.004| −0.10 | -    |
| α-toco at week 48| −0.34| 0.026| −0.04 | -    |
| α-toco at week 96| −0.21| -    | −0.19 | -    |
| Week 48/baseline| −0.08 | -    | −0.05 | -    |
| Week 96/baseline| 0.04  | -    | −0.08 | -    |

Analyses were based on linear regression which assumed an additive effect of the 433V or 12G allele on Vit E metabolism (e.g. assigning the M/M, M/V and V/V genotypes to 0, 1 and 2). The association between baseline level and CYP4F2 polymorphisms was tested in all cases for each trial, while the association during treatment was tested only in the patients treated with Vit E. The r values refer to correlation coefficients.

doi:10.1371/journal.pone.0095366.t003

---

performed using the SPSS version 20.0 (SPSS Inc., IL, USA), SAS version 9.3 and data were plotted using the Graphpad Prism 6.0 (Graphpad Software, CA, USA). An overall p value of 0.05 was used as the cut-off for statistical significance.

---

**Results**

**Genotype and allele frequency**

The allele frequencies for V433M and W12G for all genotyped samples included in this study were 0.25 and 0.14, respectively, which are very comparable to the HapMap data (CEU population, 433M = 0.23%, W12G = 11%). There was also no significant deviation from Hardy-Weinberg Equilibrium in both loci (Fisher’s exact p = 0.21 for V433M and p = 0.40 for W12G).

**Comparison of Vit E levels between PIVENS and TONIC participants**

The total baseline cholesterol level of TONIC patients was significantly lower than that of the PIVENS (p<10^{-5}) (Table S1). Plasma baseline α-tocopherol levels without normalizing to total cholesterol levels was also significantly lower in TONIC samples compared to PIVENS (p<10^{-5}) (Table S1). After normalization, the baseline plasma level of α-tocopherol was still significantly lower in the TONIC group than in the PIVENS participants (p = 4.8×10^{-5}). The normalized α-tocopherol levels were then used for subsequent analyses. This normalized α-tocopherol level during the treatment period among the individuals in the PIVENS receiving Vit E was also significantly higher than the children who were treated with Vit E in TONIC trial (p = 0.003 and 0.037 for week 48 and 96 measurements, respectively) (Table 1).
Improvement in hepatocyte ballooning (p = 0.024) and in fibrosis (p = 0.018) in the entire genotyped cohort of the TONIC trial.

**Discussion**

The mechanisms underlying inter-patient variability in both pharmacokinetics (PK) and efficacy of Vit E treatment for NAFLD/NASH have previously not been investigated. Our study explored the inter-relationship between genetic factors, Vit E levels before and during treatment and histological outcomes in adults and children who participated in PIVENS and TONIC clinical trials. We found that while common *CYP4F2* functional polymorphisms especially V433M moderately affect the plasma Vit E level during treatment, they had no significant impact on the efficacy of Vit E treatment. We observed differences between adults and children patients on the associations between Vit E level during treatment and overall histological improvement and resolution of NASH. Cross-sectional comparison revealed that there were also significant differences in the baseline and on-treatment Vit E levels between adults and children in these trials. Together, these observations may suggest complex interplay between genetic variability and non-genetic factors such as age-related physiological changes and pharmacokinetics and pharmacodynamics of Vit E in NAFLD/NASH.

The Vit E treatment increased the plasma α-tocopherol levels by ~2-fold at weeks 48 and 96 in both children and adults and this observation is consistent with previous reports [24–27]. The baseline α-tocopherol level did not predict histological outcomes, but unexpectedly we observed a significant association between histological response and lower plasma α-tocopherol level among the vit E treated adults in the PIVENS trial. This inverse relationship was not attributed to the normalization of α-tocopherol level to total cholesterol level during Vit E treatment, as no significant change in total cholesterol levels between baseline and week 96 measurements was observed (p = 0.43, data not shown). Since the regulation of plasma and hepatic Vit E levels in humans especially during Vit E supplementation is complex [27], it is possible that some individuals with relatively lower plasma α-tocopherol levels may have higher hepatic α-tocopherol concentration during Vit E treatment. Alternatively, plasma α-tocopherol concentration is highly regulated by α-tocopherol transfer protein.
(α-TTP) levels in the liver, saturation of this transfer protein might be another reason why there’s relatively lower plasma α-tocopherol levels in week 96 compared to week 48 among the Vit E treated adults [26–28].

CYP4F2 polymorphisms have been demonstrated to be functional in changing the CYP4F2 activity [14–23]. Notably, in a recent genome-wide association study (GWAS) involving over 4,000 individuals, V433M was identified as one of the top genetic factors affecting plasma Vit E level [22] and the association between Vit E with CYP4F2 was also anticipated in a recent systems biology review [29]. We observed that V433M (M allele) was significantly associated with higher baseline α-tocopherol levels in children who participated in the TONIC trial, which is consistent with the previous reports from both in vitro and in vivo investigations [14–23]. This effect was further reflected by the significant association we noted between V433M and α-tocopherol levels among Vit E treated individuals in both PIVENS and TONIC trials, suggesting that CYP4F2 polymorphisms may indeed impact the pharmacokinetics of Vit E. However, the associations between V433M and various histological outcomes were not significant. This could well be due to our small size, especially in the Vit E treated arm (n = 73 and 50 for PIVENS and TONIC trial, respectively). A recent GWAS identified other genetic variants (e.g., rs964184 at the BUD13/2F259/APOD4 locus) that affect the circulating level of Vit E [22]. In addition, there are also several important factors associated with Vit E absorption, transport and disposition, e.g. α-tocopherol transport protein (α-TTP) [26,30], where certain polymorphisms in the promoter region of this gene has been depicted previously to affect the TTP gene expression [31]. Whether these genetic polymorphisms play a role in the histological response to Vit E in NAFLD remains unaddressed and should be investigated in future studies. Alternatively, because there were marginal significant associations noted between V433M genotypes and improvement in hepatocyte ballooning (p = 0.024) and in fibrosis (p = 0.018) in the entire cohort of the TONIC trial, it may be that V433M has beneficial effects on other parameters. For instance, CYP4F2 is involved in the production of 20-hydroxyecosatetraenoic acid (20-HETE), a molecule that is proinflammatory and can induce hyperlipidemia [21,22,33]. CYP4F2 is also an important endobiotic metabolizing enzyme involved in the metabolism of fatty acids such as arachidonic acid, medium and very long polyunsaturated fatty acids, eicosanoids such as leukotriene B4 (LTB4), prostaglandins and lipoxins implicating its’ importance in maintaining liver PUFA levels and inflammatory status [34–37]. Several studies have also associated CYP4F2 expression with inflammatory disorders such as celiac disease and Crohn’s disease and other diseases like cardiovascular diseases, hypertension and stroke [38–42]. A recent study reported an association between CYP4F2V433M polymorphisms and metabolic syndrome in cohort of Swedish male patients [43]. It is possible that V433M causes less inflammation and hyperlipidemia thus improves the liver histology. This further illustrates the importance of V433M polymorphism in NAFLD that warrant further investigation in a larger patient cohort.

We observed significant differences between two clinical trials in the inter-relationship between polymorphisms, Vit E level and histological response. The reasons for these differences are unclear. Besides the sample size and the dose/body weight difference, it may reflect age as an important factor affecting the absorption, distribution, metabolism and excretion (ADME) of Vit E. Due to the dynamic physiology and ontogenic variability in drug response pathway in children, ADME of many drugs in children are commonly different from that of adults. In this case, for example, with regard to the higher baseline Vit E levels in adults than in children, it is possible that adults may have slower lipoprotein turnover and thus prolonged Vit E clearance and more matured disposition than children and adolescents. Meanwhile, the disease status and pathogenesis of NAFLD/NASH in children and adults could be different as well [44], e.g. it was suggested that lower circulating Vit E may confer susceptibility to metabolic diseases in children and young adults [45]. Previous studies have also observed that young adult patients with Type I diabetes had significantly decreased ratio of α-tocopherol/lipids compared to healthy controls [46,47]. Therefore, the developmental genetics of the Vit E pathway and the disease etiology involved in children and adults are important questions which remain to be investigated.

Supporting Information

Table S1 Plasma absolute α-tocopherol and AT/CHOL ratio at baseline and during PIVENS and TONIC clinical trials. (DOCX)

Table S2 Comparison of absolute α-tocopherol levels between different treatments (p-values) at baseline and during PIVENS and TONIC clinical trials. (DOCX)

Table S3 Association between absolute α-tocopherol level during treatment and histological endpoints among Vit E treated participants in PIVENS and TONIC. (DOCX)

Acknowledgments

Members of the Nonalcoholic Steatohepatitis Clinical Research Network

Baylor College of Medicine, Houston, TX: Stephanie H. Abrams, MD, MS; Ryan Himes, MD; Rajesh KrishnaMurthy, MD; Leanol Maldonado, RN (2007–2012); Beverly Morris

Case Western Reserve University Clinical Centers:

MetroHealth Medical Center, Cleveland, OH: Patricia Brandt; Srinivasan Dasarathy, MD; Jaividhya Dasarathy, MD; Carol Hawkins, RN; Arthur J. McCullough, MD

Cleveland Clinic Foundation, Cleveland, OH: Srinivasan Dasarathy, MD; Arthur J. McCullough, MD; Mangesh Pagadala, MD; Rishi Pali, MD; Ruth Sargent, LPN; Shetal Shah, MD; Claudia Zeni, MD

Cincinnati Children’s Hospital Medical Center, Cincinnati, OH: Kimberlee Bernstein, BS, CCRP; Kim Cecil, PhD; Stephanie DeVore, MSPH (2009–2011); Rohit Kohli, MD; Kathleen Lake, MSW (2009–2012); Daniel Podberesky, MD; Crystal Slaughter, BA, CCRP; Stavra Xanthakos, MD

Columbia University, New York, NY: Gerald Behr, MD; Joel E. Lavine, MD; Ali Mencin, MD; Nadia Ovchinsky, MD; Elena Reyno, MD

Duke University Medical Center, Durham, NC: Manal F. Abdelmalek, MD; Mustafah Bashir, MD; Stephanie Baic; Anna Mae Dick, MD; Cynthia Guy, MD; Christopher Kigongi; Yi-Ping Pan; Dawn Fiercy, FNP (2004–2011); Melissa Wagner

Emory University, Atlanta, GA: Adina Alazarzki, MD; Rebecca Cleeton, MPH; Saul Karpen, MD, PhD; Nicholas Raviade; Miriam Vos, MD, MSPH

Indiana University School of Medicine, Indianapolis, IN: Elizabeth Byam, RN; Naga Chalasani, MD; Oscar W. Cummings, MD; Cynthia Fleming, RN, MSN; Marwan Ghabril, MD; Ann Klipsch, RN; Smitha Marri, MD; Jean P. Molleston, MD; Linda Ragozzino, RN; Kumar Sandrasegaran, MD; Girish Subbarao, MD; Raj Vuppalanchi, MD

Johns Hopkins Hospital, Baltimore, MD: Kimberly Pleifer, RN; Ann Scheinmann, MD; Michael Torbenson, MD

Members of the Nonalcoholic Steatohepatitis Clinical Research Network

Baylor College of Medicine, Houston, TX: Stephanie H. Abrams, MD, MS; Ryan Himes, MD; Rajesh KrishnaMurthy, MD; Leanol Maldonado, RN (2007–2012); Beverly Morris

Case Western Reserve University Clinical Centers:

MetroHealth Medical Center, Cleveland, OH: Patricia Brandt; Srinivasan Dasarathy, MD; Jaividhya Dasarathy, MD; Carol Hawkins, RN; Arthur J. McCullough, MD

Cleveland Clinic Foundation, Cleveland, OH: Srinivasan Dasarathy, MD; Arthur J. McCullough, MD; Mangesh Pagadala, MD; Rishi Pali, MD; Ruth Sargent, LPN; Shetal Shah, MD; Claudia Zeni, MD

Cincinnati Children’s Hospital Medical Center, Cincinnati, OH: Kimberlee Bernstein, BS, CCRP; Kim Cecil, PhD; Stephanie DeVore, MSPH (2009–2011); Rohit Kohli, MD; Kathleen Lake, MSW (2009–2012); Daniel Podberesky, MD; Crystal Slaughter, BA, CCRP; Stavra Xanthakos, MD

Columbia University, New York, NY: Gerald Behr, MD; Joel E. Lavine, MD; Ali Mencin, MD; Nadia Ovchinsky, MD; Elena Reyno, MD

Duke University Medical Center, Durham, NC: Manal F. Abdelmalek, MD; Mustafah Bashir, MD; Stephanie Baic; Anna Mae Dick, MD; Cynthia Guy, MD; Christopher Kigongi; Yi-Ping Pan; Dawn Fiercy, FNP (2004–2011); Melissa Wagner

Emory University, Atlanta, GA: Adina Alazarzki, MD; Rebecca Cleeton, MPH; Saul Karpen, MD, PhD; Nicholas Raviade; Miriam Vos, MD, MSPH

Indiana University School of Medicine, Indianapolis, IN: Elizabeth Byam, RN; Naga Chalasani, MD; Oscar W. Cummings, MD; Cynthia Fleming, RN, MSN; Marwan Ghabril, MD; Ann Klipsch, RN; Smitha Marri, MD; Jean P. Molleston, MD; Linda Ragozzino, RN; Kumar Sandrasegaran, MD; Girish Subbarao, MD; Raj Vuppalanchi, MD

Johns Hopkins Hospital, Baltimore, MD: Kimberly Pleifer, RN; Ann Scheinmann, MD; Michael Torbenson, MD
Mount Sinai Kravis Children's Hospital, New York, NY: Ronen Arnon, MD; Marid Boyle, CCRP.

Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago: Katie Amsden, Mark H. Fishbein, MD; Elizabeth Kirwan, RN; Saeed Mohammad, MD; Ann Quinn, MD (2010–2012); Cynthia Rigby, MD; Peter F. Whittington, MD.

Saint Louis University, St Louis, MO: Sarah Barlow, MD (2002–2007); Joe Derdoy, MD (2007–2012); Ajay Jain MD; Debra King, RN; Ann Quinn, RD (2010–2012); Cynthia Rigsby, MD; Peter F. Whitington, MD; Robert H. Lurie Children's Hospital of Chicago: Ronen Arnon, MD; Mariel Boyd, CCRP.

University of California San Diego, San Diego, CA: Brandon Ang; Sandra Arroyo; Cynthia Behling, MD, PhD; Archana Bhatt; Jennifer Collins; Ilana Doycheva, MD; Janis Durelle; Tarek Hassanein, MD (2004–2005); Joel E. Lavine, MD PhD (2002–2010); Rohit Loomba, MD, MPH; Michael Middleton, MD, PhD; Kirkinley Newton, MD; Phirim Nguyen; Mazen Noureddin, MD; Melissa Paiz; Heather Patton, RN; Jeffrey B. Schwimmer, MD; Claude Sirlin, MD; Patricia Ugalde-Nicalo.

University of California San Francisco, San Francisco, CA: Bradley Aouizerat, PhD; Nathan M. Bass, MD PhD (2002–2011); Danielle Brandeisman, MD; Linda D. Ferrell, MD; Shannon Fleck; Ryan Gill, MD, PhD; Bilal Hameed, MD; Alexander Ko; Camille Langlois; Emily Rothbaum Perito, MD; Aliya Qayyum, MD; Philip Rosenthal, MD; Nina Vlachos, MD; Yungyong Wu, MD; Arun J. Sanyal, MD; Carol Sargeant, RN, BSN, MPH (2004–2012); Ayaj Jain MD; Debra King, RN; Pat Osmack; Joan Siegner, RN; Susan Stewart, RN; Brent A. Neuschwander-Tetri, MD; Dana Romo.

University of California San Francisco-Fresno, Fresno, CA: Pradeep Atla, MD; Cathy Hurtado; Rebekah Garcia; Sonia Garcia; Emily Rothbaum Perito, MD; Aliya Qayyum, MD; Philip Rosenthal, MD; Nina Vlachos, MD; Yungyong Wu, MD; Arun J. Sanyal, MD; Carol Sargeant, RN, BSN, MPH (2004–2012); Ayaj Jain MD; Debra King, RN; Pat Osmack; Joan Siegner, RN; Susan Stewart, RN; Brent A. Neuschwander-Tetri, MD; Dana Romo.

University of Washington Medical Center and Seattle Children's Hospital, Seattle, WA: Kara Cooper; Simon Horlsen, MD; CHI Copies of Study: Karen Murray, MD; Randolph Otto, MD; Deena Rich; Matthew Yeh, MD, PhD; Melissa Young.

Virginia Commonwealth University, Richmond, VA: Sherry Boyett, RN, BSN; Laura Carucci, MD; Melissa J. Contos, MD; Michael Fuchs, MD; Amy Jones; Kenneth Kraft, PhD; Velimir AC Luketic, MD; Amy Jones; Kenneth Kraft, PhD; Velimir AC Luketic, MD; Kimberly Noble; Puneet Puri, MD; Bimaljit Sandhu, MD (2007–2009); Arun J. Sanyal, MD; Carol Sargeant, RN, BSN, MPH (2004–2012); Jolene Schlosser; Mohammad S. Siddiqui, MD; Ben Wolford; Melanie White, RN, BSN (2006–2009).

Virginia Mason Medical Center, Seattle, WA: Sarah Ackermann; Shannon Cooney; David Coy, MD; Katie Gehan; Kris V. Kovdely, MD; Maximilian Lee, MD, MPH; Tracey Pierce; Jody Mooney, MS; James C. Nelson, PhD; Lacey Sickas; Cheryl Shaw, MPH; Asma Siddiqui, MD; Chia Wang, MD; Max Van Natta, MHS; Ivana Vaughn, MP; Laura Wilson, ScM; Katherine Yates, ScM.

Author Contributions
Conceived and designed the experiments: WL NC. Performed the experiments: SA RW. Analyzed the data: SA MZ WL. Contributed reagents/materials/analysis tools: MGT KY OWC SB JM. Wrote the paper: SA WL NC. Involved in the initial clinical trial studies: WL NC MGT KY OWC SB JM.

References
1. Kim CH, Younossi ZM (2008) Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. CJCM 75: 721–729.
2. Yu AS, Keffe EB (2002) Nonalcoholic fatty liver disease. Rev Gastroenterol Dis 2: 11–19.
3. Wilford de Alwis NM, Day CP (2008) Non-alcoholic fatty liver disease: the mist gradually clears (Review). J Hepatol 48: S104–S112.
4. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, et al (2010) Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. N Engl J Med 363: 1320–1328.
5. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, et al. (2011) Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents: The TONIC Randomized Controlled Trial. JAMA 305: 1659–1668.
6. Kayden HJ, Traber MG (1993) Absorption, lipoprotein transport, and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. J Nutr Med 2: 11–19.
7. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S (2003) Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98: 2489–2490.
8. Babich M (2010) Efficacy of Vitamin E and Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents: The TONIC Randomized Controlled Trial. JAMA 303: 1659–1660.
9. Babić M (2010) Efficacy of Vitamin E and Vitamin C in the Treatment of Nonalcoholic Steatohepatitis. Prac Gastroenterol: 20–27.
10. Parks E, Traber MG (2000) The mechanisms of the vitamin E regulation: the research over the past decade and the focus on the future. Antioxid Redox Signal 2: 405–12.
11. Traber MG, Stevens JF (2011) Vitamins and E: beneficial effects from a mechanistic perspective (Review). Free Radic Biol Med 51: 1000–13.
12. Sonntag TJ, Parker RS (2002) Cytochrome P450 P450 Hydroxylase Pathway of Tocopherol Catabolism: Novel Mechanism of Regulation of Vitamin E Status. J Biol Chem 2002: 25290–25296.
13. Brigelius-Flohe R (2003) Vitamin E and drug metabolism. Biochem. Biophys. Res. Commun 305: 737–740.
14. Lundes N, Birringer M, Brigelius-Flohe R (2003) Homologous metabolic and gene activating routes for vitamins E and K. Mol Aspects 24: 337–344.
15. Parker RS, Sonntag TJ, Swanseon JE, McCormick CC (2004) Discovery, characterization, and significance of the Cytochrome P450 1a-Hydroxylase pathway of Vitamin E Catabolism. Ann. N.Y.Acad.Sci 1031: 13–21.
16. Stoc DE, Roman RJ, Flach A, Rieder MJ (2007) Functional polymorphism in human CYP2F2 decreases 20-HETE production. Physiol. Genomics 30: 74–81.
17. McDonald MG, Rieder MJ, Nakaoka M, Hisa CK, Rettie AE (2009) CYP4F2 is a vitamin K Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant. Mol Pharmacol 75: 1337–1346.
18. Caldwell MH, Asad T, Johnson JA, Gage BF, Falkowski M, et al. (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111:4106–4112.
19. Takeuchi F, McGinnis R, Bourgeois S, Barnes G, Eriksson N, et al. (2009) A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose. PLOS Genet 5: e1000433. doi:10.1371/journal.pgen.1000433.
20. Munsch A, Sharma V, Kalu S, Al-Hazzani A, Alhawat AA, et al. (2012) Association of 1347 G/A cytochrome P450 4F2 (CYP4F2) gene variant with hypertension and stroke. Mol Biol Rep 39: 1677–1682.
21. Fava C, Montagnana M, Aliprandi P, Rosberg L, Lippi G, et al. (2008) The V433M variant of the CYP4F2 is associated with ischemic stroke in Male Swedes beyond its effect on blood pressure. Hypertension 52:373–80.
22. Major JM, Yu K, Wheeler W, Zhang H, Cornells MC, et al. (2011) Genome-wide association study identifies common variants associated with circulating vitamin E levels. Hum Mol Genet 2011; 20: 3876–3883.
23. Bardowell SA, Stee DE, Parker RS (2010) Common Variants of Cytochrome P450 4F2 (CYP4F2) Exibit Altered Vitamin E-Metabolism Specific Activity. J Nutr 140: 1901–1906.
24. Mustachi DJ, Bruno RS, Traber MG (2007) Vitamins and hormones 76: 1–21.
25. Traber MG, Rader D, Acuff RV, Ramakrishnan R, Brewer HB, et al. (1998) Vitamin E dose-response studies in humans with use of deuterated RRR-alpha-tocopherol. Am J Clin Nutr 68: 847–53.
26. Lodge JK (2003) Vitamin E bioavailability in humans. J Plant Physiology 162: 721–59.
27. McDonald MG, Rieder MJ, Nakaoka M, Hisa CK, Rettie AE (2009) CYP4F2 is a vitamin K Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M Variant. Mol Pharmacol 75: 1337–1346.
32. Lai G, Wu J, Liu X, Zhao Y (2012) 20-HETE induces hyperglycemia through the cAMP/PKA-PhK-GP pathway. Mol Endocrinol. 26:1907–16.
33. Theken KN, Deng Y, Kannon MA, Miller TM, Poleyac SM, et al. (2011) Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. Drug Metab Dispos. 39: 22–9.
34. Hardwick JP (2008) Cytochrome P450 omega hydroxylase (CYP4F1) function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol 75: 2263–75.
35. Sanders RJ, Olman R, Dacremont G, Wanders RJA, Kemp S (2008) Characterization of the human ω-oxidation pathway for ω-hydroxy-very-long-chain fatty acids. FASEB J 22: 2064–71.
36. Fer M, Corcos I, Decaro Y, Plee-Gautier E, Salaun JP, et al. (2008) Cytochromes P450 family 4 are the omega hydroxylating enzymes in humans: CYP4F3B is the prominent player in PUFA metabolism.
37. Powell PK, Wolf I, Jin RV, Lasker JM (1998) Metabolism of arachidonic acid to 20-hydroxy-5,8,11,14-eicosatetraenoic acid by P450 enzymes in human liver: Involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Therapeutics 285: 1327–36.
38. Curley CR, Monsuur AJ, Wapenaar MC, Rioux JD, Wijmenga C (2006) A functional candidate screen for coeliac disease genes. J Hum Genet 51: 1215–22.
39. Costea I, Mack DR, Israel D, Morgan K, Krupoves A, et al (2010) Genes involved in the metabolism of polyunsaturated fatty acids and risk for Crohn’s disease in children and young adults. PLOS One 5: e135672.
40. Munshi A, Sharma V, Kaul S, Al-Hazzani A, Abhatvi AA, et al (2012) Association of 1347 G/A cytochrome P450 4F2 (CYP4F2) gene variant with hypertension and stroke. Mol Biol Rep 39: 1677–82.
41. Liu H, Zhao Y, Nie D, Shu J, Fu L, et al (2008) Association of a functional cytochrome P450 4F2 haplotype with urinary 20-HETE and hypertension. J Am Soc Nephrol 19: 714–21.
42. Zordoky BNM, El-Kadi AOS (2010) Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular disease. Pharmacol Ther 125: 446–63.
43. Fava G, Montagnana M, Danese E, Sjogren M Almgren P, et al (2012) The functional variant V433M of the CYP4F2 and the metabolic syndrome in Swedes. Prosta Other Lipid Mediat 98: 31–6.
44. Hsu E, Murray K (2012) Is nonalcoholic fatty liver disease in children the same disease as in adults? Clin Liver Dis. 16: 587–98.
45. Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, et al. (2004) Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 113: 1277–1287.
46. Gupta S, Sharma TK, Kaushik GG, Shekhawat VP (2011) Vitamin E supplementation may ameliorate oxidative stress in type 1 diabetes mellitus patients. Clin Lab. 57: 379–86.
47. Hernández-Marco R, Codó-C-Franch P, Pons Morales S, Del Castillo Villasencua C, Boix García L, et al. (2009) Oxidant/antioxidant status and hyperfiltration in young patients with type 1 diabetes mellitus. Pediatr Nephrol. 24: 121–7.